Ålesund, Norway, 8 October 2024

In a groundbreaking announcement, HBC Immunology (HBCI) has successfully completed xenograft studies for its innovative prostate cancer treatment, featuring its leading peptide, FT-002a. This novel oral formulation not only demonstrates remarkable efficacy but also enhances the anti-tumour activity of enzalutamide (Xtandi®), the most widely used androgen receptor inhibitor, in both indolent and aggressive prostate cancer models.

Prostate Cancer: A Critical Health Challenge

Prostate cancer continues to be the most prevalent cancer among men globally. While the majority of cases do not pose an immediate threat to life expectancy, advanced stages of the disease remain notoriously difficult to treat. Conventional hormone therapy, although a cornerstone of prostate cancer management, faces limitations as tumours often develop resistance, leading to progressive growth and dissemination. Therefore, there is an urgent need for co-therapies that can restore treatment effectiveness and combat cancer cell resistance.

Innovative Mechanism of Action

Dr. Bomi Framroze, CEO of HBCI, stated, “Iron metabolism pathways are crucial for cancer cells' growth and ability to evade treatments. Our lead peptide candidate, FT-002a, showcases great promise in enhancing cancer therapy outcomes and improving the overall health of patients.”

Evidence suggests that cancer cells require elevated iron levels for proliferation and metastasis. FT-002a not only achieved significant tumour regression but also markedly reduced biomarkers indicating free iron levels in prostate cancer tumour cells, further substantiating its proposed action mechanism.

Looking Ahead: Investigational New Drug (IND) Submission

Given these encouraging results and the established safety profile of peptidyl drugs, HBCI is gearing up for an Investigational New Drug (IND) submission for FT-002a as an oral co-therapy for prostate cancer in the fourth quarter of 2025.

A Commitment to Innovation and Health

HBC also plays a vital role in the health sector as a supplier of ingredients for both human and pet health. The company is dedicated to the development of pharmaceutical leads, with ongoing research focused on targets such as inflammatory diseases and gastrointestinal health issues, including ulcerative colitis. Notably, HBCI is also conducting clinical trials using full-spectrum omega salmon oil to enhance respiratory health among those affected by allergic asthma and urban pollution.

The company's philosophy centers on sustainability and optimal resource utilization, utilizing its innovative hydrolysis technology to maintain the quality of natural resources like salmon off-cuts.

Conclusion: Hope on the Horizon

As HBCI prepares for the next phase in the quest to combat prostate cancer, many are watching closely. Will FT-002a change the landscape of prostate cancer treatment? Only time will tell, but if the preliminary results are any indication, hope is on the horizon for patients and their families.

Stay Updated

For more updates on HBCI’s advancements in cancer research and other health initiatives, stay tuned!